Literature DB >> 14534607

Oxidation of plasma low-density lipoproteins from coronary patients with various forms of hypercholesterolemia.

V Z Lankin1, G G Konovalova, A K Tikhaze, I B Nezhdanova, A M Olfer'ev, V V Kukharchuk.   

Abstract

The duration of lag-phase of copper-induced free-radical oxidation of atherogenic LDL isolated from the plasma of coronary patients without hypercholesterolemia virtually does not differ from that of normal human LDL. On the other hand, lag-phase of plasma LDL oxidation was minimal in coronary patients with primary hypercholesterolemia without familial history and especially in patients with familial hypercholesterolemia. This can be attributed to sharply decreased content of natural lipid antioxidants in LDL of patients with familial hypercholesterolemia. However, therapy with natural antioxidant vitamin E did not modulate oxidizability of these LDL. By contrast, therapy with beta-hydroxy-beta-methylglutaryl-coenzyme A reductase inhibitor suppressing biosynthesis of ubiphenol Q induced sharp accumulation of lipoperoxides in LDL in vivo. These data suggest that reduced form of ubiquinone Q is the main antioxidant protecting LDL from free-radical oxidation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14534607     DOI: 10.1023/a:1026032728328

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN: 0007-4888            Impact factor:   0.804


  2 in total

1.  The initiation of free radical peroxidation of low-density lipoproteins by glucose and its metabolite methylglyoxal: a common molecular mechanism of vascular wall injure in atherosclerosis and diabetes.

Authors:  Vadim Lankin; Galina Konovalova; Alla Tikhaze; Konstantin Shumaev; Elena Kumskova; Margus Viigimaa
Journal:  Mol Cell Biochem       Date:  2014-07-05       Impact factor: 3.396

2.  Increased LDL susceptibility to oxidation accelerates future carotid artery atherosclerosis.

Authors:  Toshinari Aoki; Tsueko Abe; Eiji Yamada; Takayuki Matsuto; Masahiko Okada
Journal:  Lipids Health Dis       Date:  2012-01-09       Impact factor: 3.876

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.